Regeneron Pharmaceuticals, Inc.

+5.00 (+0.80%)
Earnings Announcements

Regeneron Reports Q2 Non-GAAP EPS $9.77

Published: 08/03/2022 10:58 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Regeneron Reports Second Quarter 2022 Financial and Operating Results.
Q2 Non-GAAP Earnings per Share $9.77.
Q2 GAAP Earnings per Share $7.47.
Q2 2022 Eylea® U.S. Net Sales Increased 14% Versus Q2 2021 to a Record $1.62 Billion.
Q2 2022 Dupixent® Global Net Sales(c)(recorded by Sanofi) Increased 40% to $2.09 Billion Versus Q2 2021.
Q2 2022 Revenues Decreased 44% to $2.86 Billion Versus Q2 2021; Excluding Regen-cov®(a)(b), Revenues Increased 20%.
Q2 Earnings per Share View $8.84, Revenue View $2.80 Billion -- Refinitiv Ibes Data (analyst estimates).
Sees 2022 GAAP Research and Development $3.485 Billion-$3.655 Billion.
In H2 2022, Look Forward to Advancing Our Pipeline With Important Clinical Data Readouts in Oncology and Ophthalmology.
Revenue is expected to be $2.93 Billion
Adjusted EPS is expected to be $9.84

Next Quarter Revenue Guidance is expected to be $3.13 Billion
Next Quarter EPS Guidance is expected to be $10.21

More details on our Analysts Page.